By Fineline Cube METiS TechBio (HKG: 7666) and WestVac Biopharma, an innovative vaccine and immunotherapy company led by Academician Yuquan Wei of the Chinese Academy of Sciences, officially signed a strategic cooperation framework agreement to jointly accelerate the development of next‑generation personalized mRNA cancer vaccines driven by AI — combining METiS’ proprietary NanoForge AI nano‑delivery platform with WestVac’s vaccine R&D and industrialization capabilities.
Partnership Milestone
| Item | Detail |
|---|---|
| Partners | METiS TechBio (HKG: 7666) × WestVac Biopharma |
| Agreement | Strategic cooperation framework agreement |
| Signing Date | 21 Aug 2026 |
| Focus | AI‑driven personalized mRNA cancer vaccines |
| Key Platforms | METiS NanoForge (AI nano‑delivery) + WestVac vaccine R&D and industrialization platform |
| Leadership Context | WestVac led by Academician Yuquan Wei, Chinese Academy of Sciences |
Technology Synergy – AI Meets Vaccine Industrialization
Under the agreement, the two companies will combine METiS’ end‑to‑end Biological AI capabilities from NanoForge with WestVac’s vaccine R&D and industrialization platform. Driven by AI, both sides will jointly explore applications in AI‑assisted personalized antigen screening, design, and delivery — accelerating the innovation and clinical translation of next‑generation personalized mRNA cancer vaccines.
| Partner | Contribution |
|---|---|
| METiS TechBio | Core NanoForge platform technologies, including AiLNP and AiRNA |
| WestVac Biopharma | Industrial expertise in antigen design, vaccine manufacturing processes, and clinical development |
Strategic Rationale
- AI‑Accelerated Design: NanoForge’s AiLNP and AiRNA modules apply AI across the delivery and RNA design stack, aiming to compress timelines and improve precision in personalized vaccine construction
- Industrialization Edge: WestVac contributes proven capabilities in translating vaccine science into manufactured, clinically developed products — a critical bridge from algorithm to clinic
- Personalization at Scale: The partnership targets the core challenge of personalized oncology: rapidly tailoring mRNA cancer vaccines to individual tumor antigen profiles with reproducible manufacturing
- Clinical Translation Focus: Both parties emphasize moving beyond discovery toward clinical implementation, positioning the collaboration to pursue regulatory‑grade development
Market Impact & Outlook
- Hot Convergence: The deal reflects the accelerating convergence of AI and biotech, as investors and pharma increasingly back AI‑native platforms that promise faster, cheaper drug design cycles
- Personalized Vaccine Race: Personalized mRNA cancer vaccines have emerged as one of oncology’s most competitive frontiers, with global players pursuing neoantigen‑based approaches and combination strategies with immunotherapy
- Platform Validation: For METiS, the partnership validates NanoForge’s commercial relevance and extends its Biological AI stack into vaccine applications with a seasoned industrialization partner
- China Biotech Signal: The collaboration underscores China’s growing strength in AI‑driven biotech, pairing listed techbio (HKG: 7666) with academician‑led vaccine innovation
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the METiS‑WestVac strategic cooperation, technology development, and clinical translation of personalized mRNA cancer vaccines. Actual results may differ due to risks including scientific feasibility, regulatory pathways, competitive dynamics, and commercialization timelines.-Fineline Info & Tech